Biological Subtypes of Breast Cancer

  • Sara E. Barnato
  • William J. Gradishar
Part of the Medical Radiology book series (MEDRAD)


Breast cancer is no longer thought of as a single disease, but rather as collection of subtypes characterized by molecular signatures. The use of gene array analysis has provided insights into the dominant driver pathways that effect individual tumors and translate into clinical manifestations of the disease, response to treatment and overall clinical outcome.


Breast Cancer Molecular Subtype HER2 Receptor Adjuvant Trastuzumab Luminal Subtype 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Bertucci F, Finetti P et al (2005) Gene expression profiling identifies molecular subtypes of inflammatory breast cancer. Cancer Res 65:2170–2178CrossRefPubMedGoogle Scholar
  2. Carey LA, Dees EC et al (2007) The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13:2329–2334CrossRefPubMedGoogle Scholar
  3. Cheang MC, Chia SK et al (2009) Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101:736–750CrossRefPubMedCentralPubMedGoogle Scholar
  4. Colleoni M, Rotmensz N et al (2004) Minimal and small size invasive breast cancer with no axillary lymph node involvement: the need for tailored adjuvant therapies. Ann Oncol 15:1633–1639CrossRefPubMedGoogle Scholar
  5. Colleoni M, Viale G et al (2008) Expression of ER, PGR, HER1, HER2, and response: a study of preoperative chemotherapy. Ann Oncol 19:465–472CrossRefPubMedGoogle Scholar
  6. Dent R et al (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13:4429–4434CrossRefPubMedGoogle Scholar
  7. Dent R, Hanna WM et al (2009) Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res Treat 115:423–428CrossRefPubMedGoogle Scholar
  8. Fernandez-Morales LA, Segui MA et al (2007) Analysis of the pathologic response to primary chemotherapy in patients with locally advanced breast cancer grouped according to estrogen receptor, progesterone receptor, and HER2 status. Clin Breast Cancer 7:559–564CrossRefPubMedGoogle Scholar
  9. Fisher B, Bryant J et al (1998) Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16:2672–2685PubMedGoogle Scholar
  10. Gabos Z, Sinha R et al (2006) Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer. J Clin Oncol 24(36):5658–5663CrossRefPubMedGoogle Scholar
  11. Goldstein NS, Decker D et al (2007) Molecular classification system identifies invasive breast carcinoma patients who are most likely and those who are least likely to achieve a complete pathologic response after neoadjuvant chemotherapy. Cancer 110:1687–1696CrossRefPubMedGoogle Scholar
  12. Guarneri V, Broglio K et al (2006) Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 24:1037–1044CrossRefPubMedGoogle Scholar
  13. Haffty BG, Yang Q et al (2006) Locoregional relapse and distant metstasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 24:5652–5657CrossRefPubMedGoogle Scholar
  14. Kennecke H, Yerushalmi R et al (2010) Metastatic behavior of breast cancer subtypes. J Clin Oncol 28(20):3271–3277CrossRefPubMedGoogle Scholar
  15. Kuerer HM, Newman LA et al (1999) Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17:460–469PubMedGoogle Scholar
  16. Liedtke C, Mazouni C et al (2008) Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26:1275–1281CrossRefPubMedGoogle Scholar
  17. Mamounas E, Tang G et al (2010) Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node0negative, estrogen-receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. J Clin Oncol 28:1677–1683CrossRefPubMedCentralPubMedGoogle Scholar
  18. Nguyen PL, Taghian AG et al (2008) Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER2 is associated with local and distant recurrence after breast-conserving therapies. J Clin Oncol 26:2373–2378CrossRefPubMedGoogle Scholar
  19. Park S et al (2012) Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry. Breast 21:50–57CrossRefPubMedGoogle Scholar
  20. Perou CM, Sorlie T et al (2000) Molecular portraits of human breast tumours. Nature 406:747–752CrossRefPubMedGoogle Scholar
  21. Rody A, Karn T et al (2007) The erb2+ cluster of the intrinsic gene set predicts tumor response of breast cancer patients receiving neoadjuvant chemotherapy with docetaxel, doxorubicin and cyclophosphamide within the GEPARTRIO trial. Breast 16:235–240CrossRefPubMedGoogle Scholar
  22. Rouzier R, Perou CM et al (2005) Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11:5678–5685CrossRefPubMedGoogle Scholar
  23. Sanchez-Munoz A, Garcia-Tapiador AM et al (2008) Tumour molecular subtyping according to hormone receptors and HER2 status defines different pathological complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Clin Trans Oncol 10:646–653CrossRefGoogle Scholar
  24. Sihto H, Lundin J et al (2011) Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study. Breast Cancer Res 13:R87CrossRefPubMedCentralPubMedGoogle Scholar
  25. Sorlie T, Perou CM et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869–10874CrossRefPubMedCentralPubMedGoogle Scholar
  26. Sorlie T, Tibshirani R et al (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100:8418–8423CrossRefPubMedCentralPubMedGoogle Scholar
  27. Sotiriou C et al (2003) Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 100:10393–10398CrossRefPubMedCentralPubMedGoogle Scholar
  28. van’t Veer LJ, Dai H et al (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415(6871):530–6Google Scholar
  29. Viani G, Afonso S et al (2007) Adjuvant trastuzumab in the treatment of her-2 positive early breast cancer: a meta-analysis of published randomized trials. BMC Cancer 7:153CrossRefPubMedCentralPubMedGoogle Scholar
  30. Voduc K, Cheang M et al (2010) Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 28:1584–1691CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  1. 1.Northwestern UniversityChicagoUSA

Personalised recommendations